Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RBGLY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RBGLY and 80,000+ other tickers.
See exactly how RBGLY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RBGLY and 80,000+ other tickers.
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
Jefferies has upgraded Reckitt Benckiser Group PLC (LSE:RKT, FRA:3RB, XETRA:3RB)to 'buy' from 'hold', raising its price target to 5,900p from 5,600p ahead of half-year results next week. The broker argues the market has overly discounted a run of setbacks that hit the consumer goods group in early 2026, most of which it classes as one-off and unlikely to recur beyond this year.
Reckitt Benckiser is experiencing a market overreaction to the downside, creating an attractive entry point below £46/share. RBGLY's recent share price decline is driven by temporary macro headwinds—oil price sensitivity and a weak cold/flu season—not by fundamental business weakness. I have rebased my valuation to a 15x P/E multiple, lowering my price target to £46/share, and now rate the stock a 'Buy.'
Reckitt Benckiser Group LON: RKT executives used an investor “Focus On” event to outline how the company is applying digital science, artificial intelligence and predictive modeling across its innovation process, saying the capabilities are intended to support faster product development, stronger launch execution and efficiency gains.
UBS sees nearly 60% total return potential in Reckitt Benckiser Group PLC (LSE:RKT, FRA:3RB, XETRA:3RB with the Swiss bank repeating a Buy rating and 7,400p price target. It comes after a meeting with the consumer goods group's finance chief reinforced confidence in 2026 targets, even as the broker acknowledged the Dettol and Durex owner has become a “show me story”.
Reckitt Benckiser Group plc (RBGLY) Q1 2026 Sales/Trading Call Transcript